The Diablo 3 Necromancer Closed Beta Has Begun

Discussion in 'Diablo' started by LockDown, Apr 12, 2017.

  1. LockDown

    LockDown Moderator

    Closed beta has begun for Diablo III, Necromancer class is now available for test. If you have been selected for the Necromancer closed beta, this will show up on your Blizzard Account Management page. From the drop down menu you can select the Necromancer Beta Test in the launcher to install and start. Characters from Diablo III are available for Copy to be used on the Beta test.


    • New Feature: Challenge Rifts
      • Explore new builds created by fellow players in a weekly static dungeon. You can access these through the main screen, similar to Adventure Mode and Campaign Mode.
        • Note: New Challenge Rifts may be available more frequently during the beta.
    • New Class: Necromancer
      • As a master of the dark arts, you wield the powers of life and death necessary to restore the Balance! Necromancers are powerful spell casters who lay waste to their enemies using curses and reanimation—along with an obedient cadre of pets. This new class employs a controlled gameplay style using the raw materials of life: blood and bone.
    • New Zones: The Moors & The Temple of the Firstborn
      • The fog-enshrouded Moors and the darkened Temple of the Firstborn can be explored in Adventure Mode through a new waypoint on the Act 2 map.
    • Set Dungeons
      • The user interface has been updated to better explain tier completion requirements.
      • With this, the basic completion tier must be finished within the given time limit.
    • Bounties
      • Four new Waypoints have appeared in Act IV. Each one has bounties to complete. These Realms of Fate are the unintended consequences of the battle between the nephalem and Diablo in the High Heavens.

    source via Diablo III News

Similar Diablo Topics


Share This Page

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.
    Dismiss Notice